The IFSO questionnaire for one anastomosis /minigastric bypass (OAGB/MGB)
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Related Articles
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
OCE Conversations on Cancer – Introducing Project Connect: A World-Wide Forum for Patients with Cancer
Take this survey powered by surveymonkey.com. Create your own surveys for free.
An obscure health insurance alternative is seeing tremendous growth. But there’s a catch.
Fed up by unaffordable costs and insurance denials, more and more Americans are fleeing the conventional health care system.
A Path Forward For The US Health Insurance Industry
A path forward for the US health insurance industry following the mixed public reaction to United Healthgroup CEO Brian Thompson’s tragic murder.
Dan Haar: How Ozempic, Wegovy are costing Connecticut taxpayers $60 million this year
That $60 million price tag is up from $38 million in the last fiscal year, and $16…
Annual U.S. Dementia Cases Projected to Rise to 1 Million by 2060
A new study finds that dementia cases will increase at a much higher rate than expected, with lifetime risk rising to 42 percent after age…
2024 Tumor Board Tuesday Evaluation
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531 – Kailera
– Statistically significant mean weight loss of 22.8% (21.1% placebo adjusted) at 36 weeks; 59% of HRS9531-treated participants lost 20% or more of their baseline…
Annual U.S. Dementia Cases Projected to Rise to 1 Million by 2060
A new study finds that dementia cases will increase at a much higher rate than expected, with lifetime risk rising to 42 percent after age…
Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
Aims To examine the cardiovascular safety of combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with aspirin in individuals with obesity, both with and without type…